Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
PR Newswire —
SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of...